Arbutus Reports Fourth Quarter and Year End 2020 Financial Results and Provides Corporate UpdateGlobeNewsWire • 03/04/21
Is a Surprise Coming for Arbutus Biopharma (ABUS) This Earnings Season?Zacks Investment Research • 03/03/21
Assembly Bio/Arbutus Bio Start Testing Vebicorvir/AB-729 Triplet Therapy In HBV InfectionBenzinga • 02/26/21
Assembly Biosciences and Arbutus Biopharma Initiate Phase 2 Clinical Trial of Triple Combination Therapy for the Treatment of Chronic Hepatitis B VirusGlobeNewsWire • 02/26/21
Arbutus: A Promising Pure-Play On The $2.13 Billion Global Hepatitis B MarketSeeking Alpha • 01/25/21
Arbutus to Participate in Virtual Fireside Chat at H.C. Wainwright BioConnect 2021 ConferenceGlobeNewsWire • 01/04/21
Arbutus Announces Robust HBsAg Decline Data with AB-729 Dosed at 60 mg Every 8 Weeks in Chronic Hepatitis B SubjectsGlobeNewsWire • 12/10/20
Arbutus Announces Additional Robust HBsAg Decline Data with AB-729 in Chronic Hepatitis B SubjectsGlobeNewsWire • 11/16/20
Arbutus Announces Presentation of Phase 1a/1b Clinical Trial Results for AB-729 in Chronic Hepatitis B Subjects at The Liver Meeting Digital Experience™, The American Association for the Study of Liver Diseases MeetingGlobeNewsWire • 11/15/20
Arbutus Biopharma Corporation (ABUS) CEO Bill Collier on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 11/05/20
Will Arbutus Biopharma (ABUS) Report Negative Q3 Earnings? What You Should KnowZacks Investment Research • 10/28/20
Arbutus to Participate in Virtual Fireside Chat at Chardan’s 4th Annual Genetic Medicines ConferenceGlobeNewsWire • 09/28/20
Arbutus Announces AB-729 90 mg Single-Dose Week 12 Data in Chronic Hepatitis B Subjects Demonstrating Significant and Continuous Reductions in HBsAgGlobeNewsWire • 09/15/20
Arbutus to Participate in Virtual Fireside Chat at H.C. Wainwright 22nd Annual Global Investment ConferenceGlobeNewsWire • 09/09/20
As CDC Issues Notice, Stock Market Bets Which Company Gets First COVID-19 Vaccine FDA Approval24/7 Wall Street • 09/02/20
Assembly Biosciences and Arbutus Biopharma Announce Clinical Collaboration Agreement to Evaluate the Combination of Core Inhibitor ABI-H0731 with RNAi Therapeutic AB-729 in Patients with Chronic Hepatitis B Virus InfectionGlobeNewsWire • 08/27/20
Are Options Traders Betting on a Big Move in Arbutus Biopharma (ABUS) Stock?Zacks Investment Research • 08/26/20
Arbutus Biopharma Corporation (ABUS) CEO Bill Collier on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 08/07/20
Arbutus Reports Second Quarter 2020 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/07/20